rss
Br J Ophthalmol 2006;90:314-317 doi:10.1136/bjo.2005.080895
  • Clinical science
    • Extended reports

Effect of non-steroidal anti-inflammatory ophthalmic solution on intraocular pressure reduction by latanoprost in patients with primary open angle glaucoma or ocular hypertension

  1. T Chiba,
  2. K Kashiwagi,
  3. N Chiba,
  4. S Tsukahara
  1. Department of Ophthalmology University of Yamanashi Faculty of Medicine, Tamaho Yamanashi Japan
  1. Correspondence to: Kenji Kashiwagi MD, Department of Ophthalmology, University of Yamanashi Faculty of Medicine, 1110 Shimokato, Tamaho, Yamanashi 409-3898, Japan; kenjik{at}yamanashi.ac.jp
  • Accepted 4 October 2005

Abstract

Aim: To investigate the effects of a non-steroidal anti-inflammatory drug (NSAID) ophthalmic solution on latanoprost induced intraocular pressure (IOP) reduction in glaucoma patients.

Methods: Examination was conducted on 16 eyes of 16 glaucoma patients who had been given only latanoprost for at least 6 weeks. The NSAID ophthalmic solution, sodium 2-amino-3-(4-bromobenzoyl) phenylacetate sesquihydrate, was additionally given for 12 weeks into one eye (NSAID group), while sodium hyaluronic acid ophthalmic solution was administered into the other eye (control group) in a double masked fashion. The IOP measurement was performed before the start of additional administration of ophthalmic solutions, 2, 4, 6, 8, 10, and 12 weeks after the start of additional administration, and 2, 4, and 6 weeks after discontinuing additional administration.

Results: No significant difference was observed in the IOPs before additional administration of ophthalmic solution between the NSAID group and the control group. Following the additional administration of ophthalmic solution, IOP in the NSAID group was consistently higher than that in the control group, and a maximum difference in IOP between the two groups was 1.08 (SD 1.75) mm Hg (p = 0.03). This trend was observed even after additional administration was discontinued.

Conclusion: NSAID ophthalmic solution may partly affect IOP reduction by latanoprost.

Footnotes

  • Proprietary interest: none.

  • Ethics approval: This study was conducted in accordance with the Helsinki declaration after receipt of approval from the ethics committee of Yamanashi University. The subjects were adequately informed of the study and written consent was obtained from all of them.

Responses to this article

  • Effect of topical NSAID on IOP reduction by latanoprost
    • Ciro Costagliola,
    • Francesco Parmeggiani, Clinica Oculistica, Università di Ferrara, Italy
    Br J Ophthalmol published online September 14, 2009

This Article

  1. Abstract
  2. Full text
  3. PDF

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.